Premium
Dose escalation pharmacokinetics of intranasal scopolamine gel formulation
Author(s) -
Wu Lei,
Boyd Jason L.,
Daniels Vernie,
Wang Zuwei,
Chow Diana SL.,
Putcha Lakshmi
Publication year - 2015
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.391
Subject(s) - pharmacokinetics , motion sickness , nasal administration , transdermal , bioavailability , cmax , medicine , pharmacology , dosing , absorption (acoustics) , scopolamine , oral administration , placebo , pharmacodynamics , anesthesia , physics , alternative medicine , pathology , acoustics , radiology
Astronauts experience Space Motion Sickness requiring treatment with an anti‐motion sickness medication, scopolamine during space missions. Bioavailability after oral administration of scopolamine is low and variable, and absorption form transdermal patch is slow and prolonged. Intranasal administration achieves faster absorption and higher bioavailability of drugs that are subject to extrahepatic, first pass metabolism after oral dosing. We examined pharmacokinetics of 0.1, 0.2, and 0.4 mg doses of the Investigational New Drug formulation of intranasal scopolamine gel (INSCOP) in 12 healthy subjects using a randomized, double‐blind cross‐over study design. Subjects received one squirt of 0.1 g of gel containing either 0.1 mg or 0.2 mg/0.1 mL scopolamine or placebo in each nostril. Serial blood samples and total urine voids were collected after dosing and drug concentrations were determined using a modified LC‐MS‐MS method. Results indicate dose‐linear pharmacokinetics of scopolamine with linear increases in C max and AUC within the dose range tested. Plasma drug concentrations were significantly lower in females than in males after administration of 0.4 dose. All three doses were well tolerated with no unexpected or serious adverse side effects reported. These results suggest that intranasal scopolamine gel formulation (INSCOP) offers a fast, reliable, and safe alternative for the treatment of motion sickness.